Reviva Pharmaceuticals Holdings, Inc. RVPH

Healthcare Biotechnology

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system and respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

NDAQ:RVPH - Post by User

Reviva Pharmaceuticals Holdings, Inc.

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Sep 26, 2024 11:33am

25 Views

Post# 36242322

Reviva Pharmaceuticals to Participate in the Lytham Partners

NEWS: $RVPH Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor ConferenceCUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous sys...RVPH - Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features